|Articles|January 1, 2003

January 2003
Volume 9
Issue 1

Identifying Individuals at Risk for the Development of Type 2 Diabetes Mellitus

Author(s)Teresa L. Pearson, MS, RN, CDE, Nicolaas P. Pronk, PhD, Agnes W. H. Tan, PhD

Download PDF: Identifying Individuals at Risk for the Development of Type 2 Diabetes Mellitus

Articles in this issue

over 23 years ago

Article

Effects of Ambulatory-Care Pharmacist Consultation on Mortality and Hospitalization

over 23 years ago

Article

Impact of an Antidepressant Management Program on Medication Adherence

over 23 years ago

Article

Efficacy of Inhaled Corticosteroids Administered Once Daily for Asthma

over 23 years ago

Article

Medicaid Managed Care: Are Academic Medical Centers Penalized by Attracting Patients With High-Cost Conditions?

over 23 years ago

Article

The Cost Effectiveness of 5 Interventions to Increase Mammography Adherence in a Managed Care Population

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Identifying Individuals at Risk for the Development of Type 2 Diabetes Mellitus

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia

Cardiology Prices Vary Widely by Insurer and State

Hepatitis Prevention Programs Improve Liver Outcomes, but Gaps in Screening, Care Remain

Medicaid MFN Pricing Could Save $8.6 Billion